discogenic


Also found in: Medical.
Translations

dis·co·gen·ic

, diskogenic
a. discogénico, rel. a un disco intervertebral.
References in periodicals archive ?
IDCT is a homologous, allogeneic, injectable cell therapy that utilizes biomedically engineered progenitor cells, known as Discogenic Cells, which have been derived from intervertebral disc tissue to offer a non-invasive, potentially regenerative solution for mild to moderate DDD.
IDCT is a homologous, allogeneic, injectable cell therapy that utilizes biomedically engineered progenitor cells, known as Discogenic Cells, that have been derived from intervertebral disc tissue to offer a non-invasive, potentially regenerative solution for the treatment of mild to moderate DDD.
Beginning with fundamentals, chapters discuss historical background, the anatomy of the spine, the biomechanical role of spine structures, degenerative disc disease and discogenic pain, operating room layout, and business considerations.
Subsequently it has been found to be highly specific to discogenic pain and is not observed in patients with confirmed SIJ pain or facet joint pain.
Discogenic pain may heal incompletely or relapse without alleviating causative factors such as instable vertebral segments, carrying heavy loads, and hard working conditions.
The system can currently be used to treat chronic sacroiliac joint pain, symptomatic discogenic pain, lumbar medial branch neurotomy, chronic thoracic facet pain, and cervical pain.
MRI findings do not match with intensity of pain and disability in case of discogenic back pain.
SALT LAKE CITY, January 7, 2019 --DiscGenics, Inc., announced that its first product candidate, IDCT, an allogeneic (off-the-shelf), injectable (non-surgical) cell therapy that uses proprietary Discogenic Cells to treat degenerative disc disease, has passed the initial planned safety review of its Phase 1/2 trial.
SALT LAKE CITY, January 7, 2019 -- DiscGenics, Inc., announced that its first product candidate, IDCT, an allogeneic (off-the-shelf), injectable (non-surgical) cell therapy that uses proprietary Discogenic Cells to treat degenerative disc disease, has passed the initial planned safety review of its Phase 1/2 trial.
Discogenic pain is one of the most important causes of low back pain and it is thought that LL and changes in sacral parameters are very important causes of discogenic pain.
The prevalence of low back pain, observed in every culture and ethnic group, is reported as nearly 84%.1 The rate of chronic back pain is about 10%.2 Discogenic low back pain, whether accompanied by radicular symptoms or not, is one of the common causes of low back pain.3 There are a variety of conservative treatment methods for low back pain, led by lumbar radicular symptoms.